DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

Expert Comments:

Management Q&A: View From the Top
James Brown
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology.
read more >
Grant Zeng, Zacks Equity Research (3/15/17)
"DURECT Corp.'s two Phase III candidates are Posimir and Remoxy. . .the company has initiated a new Phase III PERSIST trial with its clinical candidate Posimir. We estimate top line data will be available soon and the FDA approval will take place in late 2017 or early 2018. . .among the company's multiple candidates, we are especially optimistic about the company's epigenomic regulator program DUR-928, which holds great potential for multiple indications, such as NASH and acute kidney injury. . .our fair value for DURECT is $6.00 per share."

Jim Molloy, Laidlaw & Company (3/15/17)
"It is the expectation that the Sisyphean development of DURECT Corp.'s Posimir may be drawing to a conclusion. DRRX anticipates completing enrollment in the ongoing Phase 3 trial in 3Q17, which should mean top line data by year end-2017. . .the company will continue to enroll DUR-928 kidney and liver trials and presenting early data gathered to date through 2017. . .DRRX plans to start a Phase 2 trial in an oral formulation for primary sclerosing cholangitis. . .should Posimir read out positively and DUR-928 get out of Phase 1 trials, DRRX is an undervalued story here. We maintain our Buy rating, and our $3 price target."

Ed Arce, H.C. Wainwright & Co. (3/15/17)
"Near-term catalyst is DURECT Corp.'s Phase 1b data readout of DUR-928 in NASH patients at EASL, on April 19-23. . .results from two STAM NASH mouse models are planned to be presented at the AASLD Emerging Trends Conference 2017 in Washington D.C. on March 17. . .Beyond NASH, DURECT disclosed its Phase 2 development plans in an orphan disease, primary sclerosing cholangitis (PSC). . .DURECT provided a 4Q16 earnings update and indicated that they are actively working towards commencing a Phase 2 trial with an oral formulation of DUR-928 for PSC."

Ed Arce, H.C. Wainwright & Co. (2/28/17)
"Given the clean safety profile and biomarker activity observed in DURECT Corp.'s Phase 1 studies of NASH and renally impaired patients. . .we anticipate continued positive progress with DUR-928 to drive value-creating optionality for DURECT management regarding indications and potential collaborations. . .DURECT believes the drug qualifies for 5-year statutory exclusivity as a new chemical entity. . .anticipate the initiation of a Phase 2b trial in acute kidney injury, and especially a potentially positive Phase 2a readout in an undisclosed chronic cholestatic liver disease, both expected later this year, to attract investor attention and interest in the program and DRRX."

Grant Zeng, Zacks Small-Cap Research (2/15/17)
"We are especially optimistic about DURECT Corp.'s epigenomic regulator DUR-928, which holds great market potential for multiple indications, including nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and acute kidney injury; multiple Phase 2 trials will be initiated in 2017. We continue to be positive about the company's story." -Zacks Small-Cap Research

Len Yaffe, Stoc*Doc Partners (12/20/16)
"Conatus Pharmaceuticals Inc. is the third recent deal in the NASH space and points to the potential value of drugs in development for this disease. I continue to highlight DURECT Corp., whose DUR-928 looks very promising albeit in early stage clinical trials. The market capitalization of DRRX is $175 million."

More Expert Comments

Experts Following This Company

Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jim Molloy, Analyst – Laidlaw & Company
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw
Len Yaffe, Fund Manager, analyst, MD – Stoc*Doc Partners
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

DURECT Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
Two Late Stage Pain Products Addressing Large Markets
Company Holds the WW Rights to DUR-928 and POSIMIR